LivaNova (NASDAQ:LIVN) Director Francesco Bianchi Sells 1,650 Shares of Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 1,650 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $79.72, for a total value of $131,538.00. Following the completion of the transaction, the director owned 7,934 shares of the company’s stock, valued at $632,498.48. The trade was a 17.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

LivaNova Stock Up 2.8%

Shares of NASDAQ:LIVN opened at $82.40 on Thursday. The stock’s 50-day moving average price is $80.71 and its two-hundred day moving average price is $72.72. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova PLC has a 12-month low of $48.82 and a 12-month high of $85.76. The firm has a market cap of $4.54 billion, a price-to-earnings ratio of 24.38 and a beta of 0.87.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The company had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. During the same quarter in the previous year, the business earned $1.05 EPS. The firm’s revenue was up 10.8% on a year-over-year basis. On average, research analysts forecast that LivaNova PLC will post 3.77 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on LIVN. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 18th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price (up from $87.00) on shares of LivaNova in a research report on Wednesday. Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Freedom Capital raised LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Finally, Stifel Nicolaus set a $85.00 price target on LivaNova in a research note on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $84.12.

Institutional Trading of LivaNova

Several large investors have recently added to or reduced their stakes in LIVN. F m Investments LLC grew its stake in shares of LivaNova by 46.9% in the fourth quarter. F m Investments LLC now owns 114,458 shares of the company’s stock valued at $7,043,000 after buying an additional 36,543 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of LivaNova by 15.7% during the 1st quarter. Renaissance Technologies LLC now owns 183,000 shares of the company’s stock valued at $11,631,000 after buying an additional 24,900 shares during the period. Vanguard Group Inc. lifted its position in LivaNova by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 2,332,051 shares of the company’s stock worth $143,491,000 after acquiring an additional 34,812 shares in the last quarter. Maverick Capital Ltd. acquired a new position in LivaNova during the 1st quarter worth approximately $956,000. Finally, Rhenman & Partners Asset Management AB lifted its position in LivaNova by 258.5% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 190,000 shares of the company’s stock worth $11,691,000 after acquiring an additional 137,000 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.